Work

Immune reprogramming of cold tumors using TGF-β/PD-L1 bispecific antibody and armed oncolytic virus therapy

Year: 2025

Type: editorial

Abstract: Immunotherapy has revolutionized oncology; however, its efficacy remains limited by the immunosuppressive tumor microenvironment (TME). This editorial synthesizes recent advances demonstrating how rationally designed combination strategies - particularly those incorporating the transforming growth factor beta/programmed death-ligand 1 (TGF-β/PD-L1) bispecific antibody platform (YM101/BiTP) and the multi-cytokine-armed oncolytic virus VG161 - can overcome resistance mechanisms. By concurrently dismantling immunosuppressive networks, activating innate immunity and remodeling the TME, these approaches show superior preclinical activity across challenging tumor phenotypes. The integration of mechanistic insights with evolving biomarker-driven strategies heralds a new era of personalized combination immunotherapy.

Source: Advances in Clinical and Experimental Medicine

DOI: 10.17219/acem/210993

Authors: Yuchen Sun, Shengtao Hu, Ming Yi, Zhijun Dai

Institutions: First Affiliated Hospital Zhejiang University, Zhejiang University

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $754